JAN 30, 2018 09:00 AM PST

WEBINAR: Metagenomics and base modifications from long, short, and linked-reads

SPONSORED BY: Zymo Research
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Associate Professor, Department of Physiology and Biophysics, WorldQuant (WQ) Scholar, Director, WQ Init. for Quantitative Prediction, Weill Cornell Medicine
    Biography
      Dr. Christopher Mason completed his dual B.S. in Genetics and Biochemistry (2001) from University of Wisconsin-Madison, his Ph.D. in Genetics (2006) from Yale University, and then completed post-doctoral training in clinical genetics (2009) at Yale Medical School, and a joint post-doctoral Fellow of Genomics, Ethics, and Law at Yale Law School (2009). He is currently an Associate Professor at Weill Cornell Medicine, with appointments at the Tri-Institutional Program on Computational Biology and Medicine, the Meyer Cancer Center, and the Feil Family Brain and Mind Research Institute.
      The Mason laboratory develops and deploys new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and human physiology. We create and explore novel techniques in next-generation sequencing and algorithms for: tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. We also work closely with NIST/FDA to build international standards for these methods, to ensure clinical-quality genome measurements/editing. We also work with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which establish the molecular foundations and genetic defenses for enabling long-term human space travel.
      He has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, the Pershing Square Sohn Cancer Research Alliance Young Investigator award, the Hirschl-Weill-Caulier Career Scientist Award, the Vallee Scholar Award, the CDC Honor Award for Standardization of Clinical Testing, and the WorldQuant Foundation Scholar Award. He has >130 peer-reviewed papers that have been featured on the covers of Nature, Science, Cell Host and Microbe, Nature Biotechnology, Nature Microbiology, and many others.He was named as one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics".
    • Scientist, Zymo Research Corp.
      Biography
        Dr. Shuiquan Tang is currently a research scientist at Zymo Research. He received his Ph.D. in the Department of Chemical Engineering and Applied Chemistry from the University of Toronto. Dr. Tang joined Zymo Research in 2014, and has since been instrumental in the research and development of Zymo's microbiomics and metagenomics programs. His past experiences include work in the fields of environmental microbiology and biological process engineering, with an emphasis on bioinformatics, metagenomics and anaerobic cultivation. Most recently, Dr. Tang has been involved in the development of Zymo Research's microbiomics portfolio. He has multiple publications in different journals, including Frontiers in Microbiology, Applied & Environmental Microbiology and Philosophical Transactions of the Royal Society of London, Series B, Biological Science.

      Abstract:

      DATE: January 30, 2018
      TIME: 9:00AM PST, 12:00PM EST

      Infectious disease surveillance and monitoring is critical in settings where disease outbreaks and antibiotic resistance can dramatically impact human health.  Rapid and accurate detection of human pathogens between closely related strains and across phylogenetic kingdoms is paramount to mitigate disease outbreaks and to diagnose affected individuals.  Here, we use demonstrate cross-kingdom species detection by simultaneously sequencing DNA from 8 bacteria and 2 fungi in the ZymoBIOMICS control.  We test this on long-read (PacBio, oxford nanopore), short read (Illumina), and linked, long-read (10x Genomics) platforms.  We also show that these standard aliquots can be used for benchmarking a variety of tools and also characterize their epigenetic changes (base modifications).  These standards are now being used internationally as part of a large-scale effort and improving metagenomics use in the clinic, or “precision metagenomics.” 

      Learning Objectives:

      • Describe the impact of a sickness on the proportion of natural flora.

      • List tools implemented for microbiome and metagenome data analysis and species detection, such as BLAST, MetaPhlAn, and CLARK

      • Describe the utility of metagenome standards and benchmarking measures

      • List the most prevalent bacteria of the skin, gastrointestinal (GI) tract, oral cavity, and urogenital tract


      Show Resources
      You May Also Like
      MAY 03, 2018 11:00 AM PDT
      MAY 03, 2018 11:00 AM PDT
      DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
      MAY 22, 2018 08:00 AM PDT
      C.E. CREDITS
      MAY 22, 2018 08:00 AM PDT
      DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
      APR 27, 2018 10:00 AM PDT
      C.E. CREDITS
      APR 27, 2018 10:00 AM PDT
      DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
      JUN 29, 2018 09:00 AM PDT
      C.E. CREDITS
      JUN 29, 2018 09:00 AM PDT
      DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
      MAY 24, 2018 09:30 AM PDT
      C.E. CREDITS
      MAY 24, 2018 09:30 AM PDT
      DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
      AUG 15, 2018 08:00 AM PDT
      C.E. CREDITS
      AUG 15, 2018 08:00 AM PDT
      DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
      Loading Comments...